Literature DB >> 10678928

Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7.

E Kita1, Y Yunou, T Kurioka, H Harada, S Yoshikawa, K Mikasa, N Higashi.   

Abstract

In a previous study, we showed that infection with Shiga toxin (Stx)-producing Escherichia coli O157:H7 (strain Sm(r)N-9) caused neurologic symptoms in malnourished mice with positive immunoreactions of Stx2 in brain tissues. The present study explores the mechanism of how Stx injures the vascular endothelium to enter the central nervous system in mice. Oral infection with strain Sm(r)N-9 elicited a tumor necrosis factor alpha (TNF-alpha) response in the blood as early as 2 days after infection, while Stx was first detected at 3 days postinfection. In the brain, TNF-alpha was detected at day 3, and its quantity was increased over the next 3 days. Frozen sections of the brains from moribound mice contained high numbers of apoptotic cells. Glycolipids recognized by an anti-Gb3 monoclonal antibody were extracted from the brain, and purified Stx2 was able to bind to the glycolipids. In human umbilical vascular endothelial cells (HUVEC) cultured with fluorescein-labeled Stx2 (100 ng/ml), TNF-alpha (20 U/ml) significantly facilitated the intracellular compartmentalization of fluorescence during 24 h of incubation, suggesting the enhanced intracellular processing of Stx2. Consequently, higher levels of apoptosis in HUVEC were found at 48 h. Short-term exposure of HUVEC to Stx2 abrogated their apoptotic response to subsequent incubation with TNF-alpha alone or TNF-alpha and Stx2. In contrast, primary exposure of HUVEC to TNF-alpha followed by exposure to Stx2 alone or TNF-alpha and Stx2 induced apoptosis at the same level as obtained after 48-h incubation with these two agents. These results suggest that the rapid production of circulating TNF-alpha after infection induces a state of competence in vascular endothelial cells to undergo apoptosis, which would be finally achieved by subsequent elevation of Stx in the blood. In this synergistic action, target cells must be first exposed to TNF-alpha. Such cell injury may be a prerequisite to brain damage after infection with Stx-producing E. coli O157:H7.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678928      PMCID: PMC97269          DOI: 10.1128/IAI.68.3.1207-1214.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  The pathogenesis of hemorrhagic colitis caused by Escherichia coli O157:H7 in gnotobiotic piglets.

Authors:  S Tzipori; I K Wachsmuth; C Chapman; R Birden; J Brittingham; C Jackson; J Hogg
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

2.  DEAE-silica gel and DEAE-controlled porous glass as ion exchangers for the isolation of glycolipids.

Authors:  S K Kundu
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

3.  Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II.

Authors:  E A Wadolkowski; L M Sung; J A Burris; J E Samuel; A D O'Brien
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

4.  Cerebral infection with Escherichia coli O157:H7 in humans and gnotobiotic piglets.

Authors:  S Tzipori; C W Chow; H R Powell
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

5.  Experimental infection of infant rabbits with verotoxin-producing Escherichia coli.

Authors:  C H Pai; J K Kelly; G L Meyers
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

6.  Quantitative isolation of total glycosphingolipids from animal cells.

Authors:  T Saito; S I Hakomori
Journal:  J Lipid Res       Date:  1971-03       Impact factor: 5.922

7.  A solvent partition method for microscale ganglioside purification.

Authors:  S Ladisch; B Gillard
Journal:  Anal Biochem       Date:  1985-04       Impact factor: 3.365

8.  The cytotoxic effect of surgical glove powder particles on adult human vascular endothelial cell cultures: implications for clinical uses of tissue culture techniques.

Authors:  J B Sharefkin; K D Fairchild; R A Albus; D F Cruess; N M Rich
Journal:  J Surg Res       Date:  1986-11       Impact factor: 2.192

9.  Monoclonal antibodies produced by immunization with neoglycoproteins containing Gal alpha 1-4Gal beta 1-4Glc beta-O and Gal alpha 1-4Gal beta 1-4GlcNAc beta-O residues: useful immunochemical and cytochemical reagents for blood group P antigens and a differentiation marker in Burkitt lymphoma and other B-cell malignancies.

Authors:  N T Brodin; J Dahmén; B Nilsson; L Messeter; S Mårtensson; J Heldrup; H O Sjögren; A Lundblad
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

10.  The human lymph node germinal center cell: characterization and isolation by using two-color flow cytometry.

Authors:  D S Weinberg; K A Ault; M Gurley; G S Pinkus
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

View more
  13 in total

1.  Bidirectional concentration-dependent effects of tumor necrosis factor alpha in Shigella dysenteriae-related seizures.

Authors:  Yael Yuhas; Abraham Weizman; Shai Ashkenazi
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.

Authors:  Kiyotaka Nishikawa; Koji Matsuoka; Eiji Kita; Noriko Okabe; Masashi Mizuguchi; Kumiko Hino; Shinobu Miyazawa; Chisato Yamasaki; Junken Aoki; Sachio Takashima; Yoshio Yamakawa; Masahiro Nishijima; Daiyo Terunuma; Hiroyoshi Kuzuhara; Yasuhiro Natori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  Direct activation of human endothelial cells by Plasmodium falciparum-infected erythrocytes.

Authors:  Nicola K Viebig; Ulrich Wulbrand; Reinhold Förster; Katherine T Andrews; Michael Lanzer; Percy A Knolle
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

4.  Rapid apoptosis induced by Shiga toxin in HeLa cells.

Authors:  Jun Fujii; Takashi Matsui; Daniel P Heatherly; Kailo H Schlegel; Peter I Lobo; Takashi Yutsudo; Georgianne M Ciraolo; Randal E Morris; Tom Obrig
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 5.  Role of Shiga/Vero toxins in pathogenesis.

Authors:  Fumiko Obata; Tom Obrig
Journal:  Microbiol Spectr       Date:  2014-06

Review 6.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

7.  Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.

Authors:  Kristin A D Sauter; Angela R Melton-Celsa; Kay Larkin; Megan L Troxell; Alison D O'Brien; Bruce E Magun
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

8.  Restricted expression of shiga toxin binding sites on mucosal epithelium of mouse distal colon.

Authors:  Yasuyuki Imai; Takashi Fukui; Kohta Kurohane; Daisei Miyamoto; Yasuo Suzuki; Tomoyuki Ishikawa; Yousuke Ono; Masaki Miyake
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

9.  Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains.

Authors:  R J F Brando; E Miliwebsky; L Bentancor; N Deza; A Baschkier; M V Ramos; G C Fernández; R Meiss; M Rivas; M S Palermo
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

10.  A translational murine model of sub-lethal intoxication with Shiga toxin 2 reveals novel ultrastructural findings in the brain striatum.

Authors:  Carla Tironi-Farinati; Patricia A Geoghegan; Adriana Cangelosi; Alipio Pinto; C Fabian Loidl; Jorge Goldstein
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.